Tango Therapeutics’ Jessica Newcomb sells shares

Both sales were made under a Rule 10b5-1 trading plan adopted June 23, 2026.

Available on EDGAR 11/04/2026 - 07:32 PM EST Accepted by SEC EDGAR 11/04/2026 - 07:32 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Tango Therapeutics, Inc. Principal Accounting Officer Jessica Newcomb sold 5,571 common shares at a weighted average price of $22.2774 per share and 1,460 common shares at a weighted average price of $22.9816 per share on November 2, 2026. Both sales were made under a Rule 10b5-1 trading plan adopted on June 23, 2026. The reported post-transaction amount includes 43,666 unvested restricted stock units, each a contingent right to receive one common share.

Insider Trade Summary 10b5-1

Net Seller: 7,031 shares

Net Sell 2 txns

Insider Newcomb Jessica

Role Principal Accounting Officer

Sold 7,031 shs ($158K)

Share of Position Sold 11.9%

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2, F3	5,571	$22.2774	$124K
Sale	Common Stock F1, F4, F3	1,460	$22.9816	$34K

Holdings After Transaction: Common Stock — 52,090 shares (Direct)

Holdings Before and After: Common Stock, 59,121 to 52,090 shares (Direct)

Footnotes (4)

1. F1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on June 23, 2026.
2. F2. Represents the weighted average sales price per share. The shares sold at prices ranging from $21.815 to $22.8149 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
3. F3. The amount reported in Column 2 includes 43,666 unvested restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.
4. F4. Represents the weighted average sales price per share. The shares sold at prices ranging from $22.82 to $23.8199 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Key Figures

Common shares sold: 5,571 shares Weighted average sale price: $22.2774 per share Common shares sold: 1,460 shares +2 more

5 metrics

Common shares sold 5,571 shares November 2, 2026 transaction

Weighted average sale price $22.2774 per share For the sale of 5,571 common shares on November 2, 2026

Common shares sold 1,460 shares November 2, 2026 transaction

Weighted average sale price $22.9816 per share For the sale of 1,460 common shares on November 2, 2026

Unvested restricted stock units 43,666 units Included in the reported post-transaction amount

Key Terms

Rule 10b5-1 trading plan, weighted average sales price, restricted stock units

3 terms

Rule 10b5-1 trading plan regulatory

"pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sales price financial

"Represents the weighted average sales price per share"

restricted stock units financial

"includes 43,666 unvested restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many TNGX shares did Jessica Newcomb sell, and at what prices?

On November 2, 2026, Jessica Newcomb sold 5,571 shares at a weighted average of $22.2774 per share and 1,460 shares at a weighted average of $22.9816 per share.

Were Jessica Newcomb's TNGX share sales made under a 10b5-1 plan?

Yes. Both sales were made under a Rule 10b5-1 trading plan adopted on June 23, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Newcomb Jessica

(Last) (First) (Middle)

C/O TANGO THERAPEUTICS, INC.

201 BROOKLINE AVE., SUITE 901

(Street)

BOSTON MASSACHUSETTS 02215

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tango Therapeutics, Inc. [ TNGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/02/2026		S(1)		5,571	D	$22.2774(2)	53,550(3)	D
Common Stock	11/02/2026		S(1)		1,460	D	$22.9816(4)	52,090(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on June 23, 2026.

2. Represents the weighted average sales price per share. The shares sold at prices ranging from $21.815 to $22.8149 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

3. The amount reported in Column 2 includes 43,666 unvested restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.

4. Represents the weighted average sales price per share. The shares sold at prices ranging from $22.82 to $23.8199 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

	/s/ Julie Fogarty, as attorney-in-fact	11/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)